Combination Chemotherapy in Treating Patients With Lymphoma

PHASE3CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

October 30, 1995

Primary Completion Date

February 4, 2004

Study Completion Date

February 4, 2004

Conditions
Lymphoma
Interventions
BIOLOGICAL

Bleomycin Sulfate (BLM)

BIOLOGICAL

Filgrastim (G-CSF)

Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.

BIOLOGICAL

Recombinant Interferon Alfa

DRUG

Carmustine

Arm 1, Course 3, IV over 1 hour on day -6.

DRUG

Cisplatin (CDDP)

DRUG

Cyclophosphamide

DRUG

Cytarabine (ARA-C)

Arm 1, Course 3, every 12 hours on days -5 to -2.

DRUG

Etoposide (VP-16)

Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.

DRUG

Idarubicin

DRUG

Ifosfamide

During Course 1, IV continuously; Course 2, IV continuously on days 1-3.

DRUG

Leucovorin Calcium

DRUG

Melphalan

DRUG

Methotrexate

DRUG

Methylprednisolone

DRUG

mitoxantrone hydrochloride (DHAD)

Arm 1, Course 2, IV on day 1.

DRUG

Vincristine Sulfate

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Infusion of stem cells on Day 0.

RADIATION

Radiation Therapy

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00002835 - Combination Chemotherapy in Treating Patients With Lymphoma | Biotech Hunter | Biotech Hunter